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A B S T R A C T
Purpose
Cytokines play a pivotal role in Hodgkin’s lymphoma (HL). Because interleukin-6 (IL-6) induces
expression of hepcidin, one of the principal regulators of iron metabolism, we studied the
contribution of hepcidin in anemia in HL at diagnosis.
Patients and Methods
Plasma samples from 65 patients with HL were analyzed for hepcidin levels using a combination
of weak cation exchange chromatography and time-of-flight mass spectrometry; cytokine levels
were analyzed using enzyme-linked immunosorbent assays and parameters of iron metabolism
and acute-phase reaction.
Results
Hepcidin plasma levels were significantly higher in HL patients when compared with controls,
independent of the presence of anemia (P .001). In the subset of patients with anemia, hepcidin
levels inversely correlated with hemoglobin levels (P  .01). Analyzing parameters of iron
metabolism, hepcidin levels showed a positive correlation with ferritin (P  .001) and an inverse
correlation to iron and iron-binding capacity. Hepcidin strongly correlated to IL-6 levels (P  .001)
but not to IL-10 or thymus and activation-regulated cytokine (TARC)/chemokine (C-C motif) ligand
17 (CCL17) levels. In a multivariate regression analysis, IL-6 and fibrinogen levels were indepen-
dently associated with hepcidin. Higher hepcidin levels were observed in patients with more
aggressive disease characteristics: stage IV disease (P  .01), presence of B symptoms (P  .03),
and International Prognostic Score  2 (P  .005).
Conclusion
Our findings suggest that in HL, hepcidin is upregulated by IL-6. Elevated hepcidin levels result in
iron restriction and signs of anemia of chronic inflammation, although hepcidin-independent
mechanisms contribute to development of anemia in HL.
J Clin Oncol 28:2538-2543. © 2010 by American Society of Clinical Oncology
INTRODUCTION
Anemia is a presenting symptom in approximately
40% of patients with Hodgkin’s lymphoma (HL). It
is more frequently observed in advanced stages and
is usually associated with B symptoms such as fever,
night sweats, and weight loss. In general, the anemia
is normochromic and normocytic and is usually
mild, with hemoglobin (Hb) levels between 10 and
12 g/dL.
The anemia of chronic disease is seen in a wide
variety of inflammatory states including acute sys-
temic inflammatory response syndrome, chronic
infections, inflammatory disorders, and some can-
cers.1,2 This iron-refractory anemia is characterized
by low serum iron (hypoferremia), reduced iron-
binding capacity, and subnormal transferrin satura-
tion, while bone marrow iron is relatively preserved.
Traditional biochemical iron indicators (eg, serum
iron, ferritin, transferrin saturation) are of only
limited use because of the distorting effects of
inflammation on their levels. Serum ferritin levels,
although useful indicators of iron status in patients
without underlying chronic disorders, increase in
patients with inflammatory diseases. Ferritin levels
have been reported to be elevated in patients with
HL, in particular in advanced stages and during dis-
ease progression.3,4
Studies in humans and mice suggest that the
iron-regulatory hormone hepcidin is the princi-
pal mediator of anemia of chronic disease and/
or inflammation.5-11 Hepcidin is a liver-produced
acute-phase peptide whose overproduction leads to
iron-limited erythropoiesis. Hepcidin binds to the
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cell membrane iron exporter ferroportin and induces its internaliza-
tion and degradation, thus decreasing iron release from macrophages
and enterocytes. Inflammatory cytokines increase the expression of
hepcidin,12,13 leading to decreased absorption of iron from the
intestine, and block the release of iron from the reticuloendothelial
system and the liver.14 Infusion of interleukin-6 (IL-6) in human
volunteers resulted in increased excretion of urinary hepcidin and
development of hypoferremia.12 IL-6 is a potent inducer of hepcidin
expression through a signal transducer and activator of transcription
3–dependent transcriptional mechanism.15-17 In addition, macro-
phages express hepcidin in response to microbial stimulation.18 A
pathogenic cascade for the development of anemia of inflammation
has been proposed that leads from IL-6 to hepcidin to hypoferremia
and, as a consequence, to anemia of inflammation.7
The inflammatory response surrounding the Hodgkin’s and
Reed-Sternberg cell is part of HL as the cell of origin itself. In the
interactions between the neoplastic Hodgkin’s and Reed-Sternberg
cells and the reactive cells of the microenvironment, there are high
levels of cytokines, such as IL-6, IL-10, and the chemokine thymus and
activation-regulated cytokine (TARC) among others.19 Local produc-
tion of these cytokines results in elevated systemic levels in the periph-
eral blood, and these cytokines are responsible for the development of
systemic symptoms and laboratory abnormalities that are correlated
with disease prognosis.20-22 IL-6 is among the cytokines most strongly
associated with anemia.20 We were interested in the contribution of
hepcidin to the pathogenesis of anemia of HL and its relation to other
cytokines important in the biology of the disease, including IL-6,
IL-10, and TARC.
PATIENTS AND METHODS
Patient Characteristics
Our analysis included 65 patients (median age, 35 years; range 15 to 83
years; 36 females and 29 males) diagnosed with HL between March 2004 and
May 2009 and observed at the Institute of Hematology of the Catholic Univer-
sity of Rome. Thirteen patients had stage IV disease, but only five patients
showed bone marrow infiltration. Of these five patients, four patients were
anemic, but only one patient had signs of reduced hematopoiesis as a result of
bone marrow infiltration. Additional patient characteristics, including the
International Prognostic Score (IPS),23 are detailed in Table 1. Peripheral
blood samples were obtained at the time of initial diagnosis, and samples were
collected early in the morning. All parameters of iron metabolism were deter-
mined in the central laboratory of the Catholic University. A group of 24
healthy individuals (median age, 41 years; range 18 to 63 years; 13 females, 11
males) was used as a control.24 Informed consent was obtained from patients
and controls according to institutional guidelines, and blood sample collection
was approved by our institutional ethical committee.
Enzyme-Linked Immunosorbent Assay for Plasma Levels of
IL-6, IL-10, and TARC
IL-6, IL-10, and TARC levels were determined in pretreatment plasma
samples, which had been stored at70°C and thawed for the first time, by
a sandwich enzyme-linked immunosorbent assay, according to the manu-
facturer’s instructions (Human IL-10 DuoSet and Human CCL17/TARC
DuoSet, R&D Systems, Minneapolis, MN; Human IL-6 US, BioSource Inter-
national, Camarillo, CA).
Hepcidin-25 Quantification
Plasma hepcidin measurements were performed in July 2009 (testing
laboratory: Hepcidinanalysis.com, Nijmegen, the Netherlands) by a combina-
tion of weak cation exchange chromatography and time-of-flight mass spec-
trometry (TOFMS). An internal standard (synthetic hepcidin-24; Peptide
International, Louisville, KY) was used for quantification (www.hepcidinan-
alysis.com).25,26 Peptide spectra were generated on a Microflex LT matrix-
enhanced laser desorption/ionisation TOFMS platform (Bruker Daltonics,
Billerica, MA). Plasma hepcidin-25 concentrations were expressed as
nmol/L. The lower limit of detection of this method was 0.5 nmol/L;
average coefficients of variation were 2.7% (intrarun) and 6.5% (inter-
run). The median reference level of plasma hepcidin-25 is 4.2 nmol/L
(range, 0.5 to 13.9 nmol/L).24
Statistical Analysis
Wilcoxon signed rank test was used for two-sample comparisons of
hepcidin plasma levels between patient and control groups or according to
dichotomized patient characteristics. Comparisons between controls and pa-
tients were also performed using analysis of covariance models including sex,
age, and ferritin levels as covariates. Since the distribution of plasma parame-
ters in our population revealed a departure from normality that was mitigated
using a logarithmic transformation, the log of the concentration was used for
testing purposes. However, untransformed values were used for reporting
results. Plasma parameters were analyzed both as continuous variables follow-
ing logarithmic transformation and as dichotomous variables using the upper
limit of normal of controls as a cutoff point. Correlations between the various
blood parameters were calculated by linear regression models. A multivariate
logistic regression model was used to examine the relationship between the
dependent variable (hepcidin plasma level) and potential predictor variables,
including Hb, IL-6, ferritin, and fibrinogen levels. Stepwise backward
elimination of nonsignificant parameters was used to obtain the best
model. Computations were performed using STATA 10.0 software (STATA,
College Station, TX).
RESULTS
Anemia and Patient Characteristics in HL
We studied 65 patients with HL at diagnosis. Anemia, defined as
Hb concentration  12 g/dL, was present in 30 patients, and it was
Table 1. Associations Between Patient Characteristics and Hemoglobin,
Hepcidin, and IL-6 Levels
Variable
No. of
Patients
Hemoglobin
(n  65)
Hepcidin
(n  59)
IL-6
(n  55)
TARC
(n  57)
g/dL P nmol/L P ng/mL P ng/mL P
Age, years .02 .03 .05 .98
 45 43 12.4 6.5 0.7 3,575
 45 22 11.2 10.4 4.1 4,529
Sex .001 .06 .5 .02
Female 36 11.3 6.9 2.1 5,223
Male 29 12.9 9.4 1.3 2,271
Stage .04 .01 .02 .37
I-III 50 12.4 6.3 0.6 3,671
IV 13 10.8 13.7 5.4 3,434
B symptoms  .001 .03 .003 .07
No 40 12.8 5.9 0.6 2,999
Yes 23 10.9 10.4 2.1 5,829
Bulky disease .21 .85 .32 .04
No 46 12.3 7.8 1.2 3,033
Yes 17 11.5 7.2 0.6 6,806
IPS  .001 .005 .002 .59
Low-risk 49 12.7 6.2 0.6 4,045
High-risk 14 9.9 12.2 3.0 3,444
NOTE. P values were determined by Mann-Whitney rank sum test.
Abbreviations: IL-6, interleukin-6; TARC, thymus and activation-regulated
cytokine; IPS, International Prognostic Score.
The IPS was calculated according to Hasenclever and Diehl.23 IPS scores
0-2 were considered as low-risk and  3 as high-risk.
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mild (Hb between 10 and 12 g/dL) in 20 patients. Anemia was normo-
cytic and normochromic in 19 patients, while it was microcytic in 11
patients. Associations of anemia with patient characteristics are pre-
sented in Table 1. As expected, Hb concentration was lower in female
patients, in patients older than age 45 years, and in patients with B
symptoms, stage IV disease, and a higher IPS score ( 2).
Hepcidin Levels and Anemia in HL Patients
Hepcidin levels in 59 patients were determined in plasma sam-
ples taken at diagnosis by using a combination of weak cation ex-
change chromatography and TOFMS. The mean hepcidin level in HL
patients was 7.9 nmol/L, ranging from below the detection limit of 0.5
nmol/L in three patients to 27.4 nmol/L, and was significantly higher
than that of a group of 24 non-anemic normal controls (mean, 2.77
nmol/L; range, 0.5 to 8.2 nmol/L; P .001). The difference between
HL patients and controls remained significant after including age and
sex and adjusting for ferritin levels (P .002), which may influence
hepcidin levels in healthy controls. Strikingly, when comparing con-
trols with non-anemic HL patients, hepcidin was still significantly
higher in HL (P .02; Fig 1).
Patients older than age 45 years had higher hepcidin levels
(P .03), and there was a borderline significance for higher hep-
cidin levels in males compared with females (P .06; Table 1). In
anemic patients, hepcidin levels inversely correlated with Hb val-
ues (r0.43; P .02; Fig 2), while there was no correlation in
the absence of anemia.
Hepcidin and Iron Metabolism in HL
Data on iron metabolism were available for 39 patients. The
median serum iron and total iron-binding capacity in HL patients
were 33 g/dL (range, 9 to 183 g/dL) and 233 g/dL (range, 154 to
366g/dL), respectively, and were lower than the normal range (40 to
150 g/dL for iron and 250 to 425 g/dL for total iron-binding
capacity). Ferritin levels showed a wide variation with a median of 90
ng/mL and a range between 7 and 7,500 ng/mL. Only three patients
had iron deficiency anemia, defined by Hb levels  12 g/dL and
microcytosis and ferritin levels 12 ng/mL.
Looking at parameters of iron metabolism, there was a strong
correlation between hepcidin and ferritin (r 0.62; P .001) and an
inverse correlation with iron and iron-binding capacity (r0.42,
P .009; and r0.43, P .02, respectively; Fig 3). After adjustment
for multiple testing, the correlation between hepcidin and parameters
of iron metabolism, but not iron itself, maintained statistical signifi-
cance (Table 2).
Correlation of Hepcidin With Levels of IL-6 and Other
Markers of Inflammation
Because hepcidin is an acute-phase reactant during infection
and/or inflammation, we examined the relationship between hepcidin
and inflammatory cytokines and other proteins of the acute-phase
reaction. Among these, ferritin, as described above, and fibrinogen
correlated with hepcidin (Table 2).
IL-6 concentration was studied in 55 patients. It was below the
detection limit of the assay (0.01 ng/mL) in 15 patients, while the mean
concentration was 2.4 ng/mL ( 6.15 ng/mL) in the remaining 40
patients. IL-6 correlated with several laboratory parameters and clin-
ical characteristics as detailed in Tables 1 and 2. In particular, IL-6
inversely correlated with Hb values (r0.49; P .001). We found
a highly significant correlation between levels of hepcidin and IL-6
(r0.55; P .001; Fig 4), whereas there was no significant correlation
with IL-10 or TARC levels, arguing against a role for these cytokines in
hepcidin upregulation in HL patients.
Because several parameters indicative for anemia of inflamma-
tion were associated with hepcidin levels, we next performed a multi-
variate analysis to predict hepcidin levels. We included Hb values and
the significant parameters from univariate analysis (Table 2): IL-6 as
the most relevant cytokine, ferritin as the most important parameter
for iron metabolism, and fibrinogen levels as the parameter for acute-
phase reaction. Using a stepwise backward regression analysis, Hb and
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Fig 1. Box plots of hepcidin plasma concentrations in healthy controls (n  24)
and patients with Hodgkin’s lymphoma (HL) at diagnosis (n  59). Patients with
HL were divided into a non-anemic group with hemoglobin levels  12 g/dL
(n  30) and an anemic group with hemoglobin levels  12 g/dL (n  29). The
upper border of the box indicates the upper quartile (75th percentile), while the
lower border indicates the lower quartile (25th percentile), and the horizontal line
in the box indicates the median. The vertical lines are the whiskers indicating the
upper and lower adjacent values. Both anemic and non-anemic patients had
significantly higher levels of hepcidin when compared with controls (P .002 and
.02, respectively), while the difference between anemic and non-anemic patients
was not statistically significant (P  .18).
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Fig 2. Correlation between hemoglobin and hepcidin in Hodgkin’s lymphoma
(HL) patients. Scatter plots with linear regression lines (black lines) and 95% CIs
(gray lines) showing significant inverse correlation between hemoglobin and
hepcidin levels in anemic HL patients (r  0.43; P  .02) but not in non-anemic
patients (r  0.04; P  .8).
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ferritin levels were excluded, while IL-6 and fibrinogen independently
correlated with hepcidin (P .03 and P .001, respectively). Rerun-
ning the model with only IL-6 and fibrinogen confirmed the results
obtained by the backward selection technique (Appendix Table A1,
online only).
Hepcidin and Clinical Characteristics
We analyzed for associations of hepcidin levels with clinical char-
acteristics with known prognostic impact. Higher hepcidin levels were
observed in patients with stage IV disease (P .01), in the presence of
B symptoms (P .03), and in patients with an IPS score3 (P .005;
Table 1).
DISCUSSION
Our study shows that hepcidin plasma levels are increased in patients
with HL. Hepcidin levels strongly correlate with changes typical for
inflammation and Hodgkin’s disease activity, such as increased IL-6
levels. Increased hepcidin was also found in non-anemic patients,
whereas in anemic patients, there was a striking inverse correlation
with the severity of anemia. It correlated with changes in iron metab-
olism that are typical for inflammation and acute-phase reaction, such
as elevated ferritin, lower iron, reduced total iron-binding capacity,
and higher fibrinogen levels. This is in line with the role of hepcidin as
a gatekeeper for iron homeostasis, inhibiting the cellular efflux of iron
through ferroportin, resulting in iron being trapped in macrophages
and iron-absorbing enterocytes and reducing the availability of iron
for erythropoiesis.
Iron redistribution is a hallmark of anemia of chronic disease.
Although some cases of anemia can be attributed to iron deficiency, in
our case series, there were only three patients with iron-deficiency
anemia; the vast majority of patients with HL who are anemic present
with anemia of chronic disease. Bone marrow infiltration as a con-
founding factor for development of anemia is rare in HL and was
present in only five patients in our case series, with only one patient
having extensive bone marrow infiltration in the biopsy that could
explain anemia.
Given its high prevalence, anemia in HL is an interesting model
for studying cytokine-mediated anemia. Experiments in mice and
clinical observations have demonstrated that anemia of chronic dis-
ease is characterized by a complex interaction between the compo-
nents of inflammation and indicate that IL-6 seems to be the principal
cytokine inducing iron-restricted erythropoiesis and anemia.2,12,27-30
IL-6 knockout mice fail to produce hepcidin in response to inflamma-
tory challenges.12,27 During inflammation, IL-6 alone can rapidly in-
duce hepcidin synthesis and corresponding hypoferremia.12 In a
patient presenting with hemochromatosis and an auto-inflammatory
disease, there was clear evidence for the IL-6–hepcidin axis in the
development of hypoferremia and anemia of inflammation.31 In cell
culture experiments, IL-6, but not IL-1 or tumor necrosis factor alpha
(TNF-), induced hepcidin mRNA expression in human hepato-
cytes.32 In myeloma patients, plasma IL-6 could induce hepcidin while
no effects for TNF-or interleukin-1 beta (IL-1) were observed.29 In
this line, we observed a strong association between IL-6 and hepcidin
in HL, while IL-10 or TARC did not play a significant role.
Because IL-6 levels more strongly correlated with development of
anemia than hepcidin levels did, other IL-6–associated mechanisms
than hepcidin-mediated iron restriction are also probably involved in
the induction of anemia in HL. Administration of recombinant hu-
man IL-6 induces a rapid-onset, dose-dependent, progressive anemia
that is quickly reversible after the cessation of therapy, with the char-
acteristics of a dilutional anemia driven by marked increases in plasma
volume.33,34 Impairment of proliferation and differentiation of ery-
throid progenitors could also contribute to IL-6–mediated anemia.
IL-6 itself does not suppress erythropoiesis and has no demonstrable
direct effect on the proliferation of hematopoietic progenitors.35 It is
even a potent megakaryopoietic growth factor and may be the hu-
moral mediator of reactive thrombosis accompanying inflammatory
states. Suppression of erythropoiesis may be due to other acute-phase
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Fig 3. Correlations between hepcidin and parameters of iron metabolism.
Scatter plots with linear regression (black lines) and 95% CIs (gray lines) show
significant correlations between hepcidin and (A) ferritin, (B) iron, and (C) total
iron-binding capacity.
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reactants induced by IL-6. Reduced expression of transferrin recep-
tors, impaired binding affinity of transferrin receptors, and inade-
quate erythropoietin production and response may contribute to the
defect of erythropoiesis in the anemia of chronic disease.2,36-38
Hepcidin levels were higher in HL patients with advanced-stage
disease and B symptoms. A similar association of elevated hepcidin
levels with advanced-stage disease has been reported for patients with
non-Hodgkin’s lymphoma and myeloma.29,39 Moreover, Ukarma et
al39 observed higher hepcidin levels in anemic patients with hemato-
logic tumors than with solid tumors. The association of hepcidin with
unfavorable prognostic factors in our HL study raises the question of
whether hepcidin may have a role as a biomarker. Anemia and IL-6
levels are well-known prognostic markers in HL,20,23,40,41 and future
studies might address the relationship of IL-6, anemia, and hepcidin
with prognosis in HL and whether these correlations will correct
after therapy.
Elevated hepcidin levels in HL may also open a perspective for
antihepcidin or anti-inflammatory therapy in reversing the anemia of
inflammation in this disease. Administration of an anti–IL-6 receptor
antibody tocilizumab in two patients with multicentric Castleman’s
disease rapidly lowered serum hepcidin levels and resulted in a prompt
Hb increase even without iron administration.42
In conclusion, we propose the following scenario: HL disease
activity is associated with production and release of IL-6 into the
systemic circulation, which stimulates the overproduction of hep-
cidin as an acute-phase reactant in the liver. Elevated levels of
hepcidin in HL correlate with iron restriction and contribute to
anemia. However, elevated hepcidin levels do not appear sufficient to
induce anemia. Other hepcidin-independent mechanisms induced by
pro-inflammatory cytokines, in particular IL-6, leading to anemia are
likely to be involved.
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Table 2. Associations Between Hepcidin, Hemoglobin, and IL-6 Levels, and Parameters of Iron Metabolism and Acute-Phase Reaction
Hepcidin
Hepcidin  1.0 Hemoglobin
No. 59
Hemoglobin  0.237 1.0 IL-6
No. 59 65
P 1.0
IL-6  0.534 0.512 1.0 Ferritin
No. 49 55 55
P .0016 .0014
Ferritin  0.612 0.002 0.589 1.0 Iron
No. 35 38 29 38
P .0020 1.0 .016
Iron  0.420 0.400 0.370 0.19 1.0 Fibrinogen
No. 37 39 31 33 39
P .2 .26 .85 1.0
Fibrinogen  0.524 0.344 0.407 0.47 0.550 1.0 Albumin
No. 53 59 50 36 36 59
P .0012 .16 .07 .08 .01
Albumin  0.10 0.601 0.470 0.12 0.195 0.02 1.0
No. 50 54 45 32 35 49 54
P 1.0  .001 .024 1.0 1.0 1.0
NOTE. Spearman rank correlation coefficients were calculated for each pair of variables;  values are given in the first line of each cell, No. indicates the number
of observations, and P indicates the significance level. Significance levels were adjusted for multiple testing using the Bonferroni correction.
Abbreviation: IL-6, interleukin-6.
Correlations with P values  .05.
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Fig 4. Correlation between hepcidin and cytokines. Scatter plot with linear
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